ITeos Therapeutics Inc

-1.06 (-4.23%)
Products, Strategic Combinations, Regulatory

GSK, Iteos Collaborate For EOS-448, Iteo To Get $625 Mln Upfront Payment

Published: 06/14/2021 11:12 GMT
ITeos Therapeutics Inc (ITOS) - Glaxosmithkline Plc - Gsk and Iteos Announce Collaboration for Eos-448.
Gsk - Eos-448 is Currently in Phase I for Advanced Solid Tumours With a Randomised Pd-1 Combination Study Planned for 2022.
Gsk - Iteos to Receive a $625 Million Upfront Payment in Addition to Potential Milestones, and Royalty Payments on Ex-us Sales.
Gsk -.
Gsk - Gsk and Iteos Will Co-commercialise and Share Profits in Us.
Gsk - Gsk Now Has Leading Portfolio of Antibodies Targeting Cd226 Axis - a Key Target for Next-generation Immuno-oncology Therapies.
Gsk - With This Collaboration Gsk is Uniquely Positioned With Access to Antibodies That Synergistically Target All Three Known Cd226 Checkpoints.
Gsk - Iteos Will Be Eligible to Receive Up to an Additional $1.45 Billion in Milestone Payments, Should Eos-448 Programme Achieve Certain Milestones.
Gsk - Within Collaboration, Gsk and Iteos Will Share Responsibility and Costs for Global Development of Eos-448.
Gsk - Expects to Submit an Investigational New Drug Application for Gsk'562 (anti-pvrig In-licensed As Srf-813 From Surface Oncology) by Mid-2022.
Gsk - Gsk and Iteos Plan to Start Combination Studies of Eos-448 With Dostarlimab in 2022.